Literature DB >> 17116919

Pharmacogenomics: challenges and opportunities.

Dan M Roden1, Russ B Altman, Neal L Benowitz, David A Flockhart, Kathleen M Giacomini, Julie A Johnson, Ronald M Krauss, Howard L McLeod, Mark J Ratain, Mary V Relling, Huijun Z Ring, Alan R Shuldiner, Richard M Weinshilboum, Scott T Weiss.   

Abstract

The outcome of drug therapy is often unpredictable, ranging from beneficial effects to lack of efficacy to serious adverse effects. Variations in single genes are 1 well-recognized cause of such unpredictability, defining the field of pharmacogenetics (see Glossary). Such variations may involve genes controlling drug metabolism, drug transport, disease susceptibility, or drug targets. The sequencing of the human genome and the cataloguing of variants across human genomes are the enabling resources for the nascent field of pharmacogenomics (see Glossary), which tests the idea that genomic variability underlies variability in drug responses. However, there are many challenges that must be overcome to apply rapidly accumulating genomic information to understand variable drug responses, including defining candidate genes and pathways; relating disease genes to drug response genes; precisely defining drug response phenotypes; and addressing analytic, ethical, and technological issues involved in generation and management of large drug response data sets. Overcoming these challenges holds the promise of improving new drug development and ultimately individualizing the selection of appropriate drugs and dosages for individual patients.

Entities:  

Mesh:

Year:  2006        PMID: 17116919      PMCID: PMC5006954          DOI: 10.7326/0003-4819-145-10-200611210-00007

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  76 in total

1.  Natural variation in human membrane transporter genes reveals evolutionary and functional constraints.

Authors:  Maya K Leabman; Conrad C Huang; Joseph DeYoung; Elaine J Carlson; Travis R Taylor; Melanie de la Cruz; Susan J Johns; Doug Stryke; Michiko Kawamoto; Thomas J Urban; Deanna L Kroetz; Thomas E Ferrin; Andrew G Clark; Neil Risch; Ira Herskowitz; Kathleen M Giacomini
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-28       Impact factor: 11.205

Review 2.  Inheritance and drug response.

Authors:  Richard Weinshilboum
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

Review 3.  Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.

Authors:  Lawrence J Lesko; Janet Woodcock
Journal:  Nat Rev Drug Discov       Date:  2004-09       Impact factor: 84.694

Review 4.  Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered.

Authors:  Lois S Lee; Anne N Nafziger; Joseph S Bertino
Journal:  Clin Pharmacol Ther       Date:  2005-07       Impact factor: 6.875

5.  The need for education in pharmacogenomics: a regulatory perspective.

Authors:  F W Frueh; F Goodsaid; A Rudman; S-M Huang; L J Lesko
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

6.  Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate.

Authors:  C Funk; M Pantze; L Jehle; C Ponelle; G Scheuermann; M Lazendic; R Gasser
Journal:  Toxicology       Date:  2001-10-05       Impact factor: 4.221

7.  Complement factor H variant increases the risk of age-related macular degeneration.

Authors:  Jonathan L Haines; Michael A Hauser; Silke Schmidt; William K Scott; Lana M Olson; Paul Gallins; Kylee L Spencer; Shu Ying Kwan; Maher Noureddine; John R Gilbert; Nathalie Schnetz-Boutaud; Anita Agarwal; Eric A Postel; Margaret A Pericak-Vance
Journal:  Science       Date:  2005-03-10       Impact factor: 47.728

Review 8.  The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development.

Authors:  D K Walker
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

9.  Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.

Authors:  Anna L Gloyn; Ewan R Pearson; Jennifer F Antcliff; Peter Proks; G Jan Bruining; Annabelle S Slingerland; Neville Howard; Shubha Srinivasan; José M C L Silva; Janne Molnes; Emma L Edghill; Timothy M Frayling; I Karen Temple; Deborah Mackay; Julian P H Shield; Zdenek Sumnik; Adrian van Rhijn; Jerry K H Wales; Penelope Clark; Shaun Gorman; Javier Aisenberg; Sian Ellard; Pål R Njølstad; Frances M Ashcroft; Andrew T Hattersley
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

10.  Genetic control of drug levels in man: phenylbutazone.

Authors:  E S Vesell; J G Page
Journal:  Science       Date:  1968-03-29       Impact factor: 47.728

View more
  71 in total

Review 1.  Child and adolescent psychiatry: past scientific achievements and challenges for the future.

Authors:  Michael Rutter
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-05-11       Impact factor: 4.785

Review 2.  The role of pharmacogenetics in nonmalignant gastrointestinal diseases.

Authors:  Michael Camilleri
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-07       Impact factor: 46.802

3.  Pharmacogenetics: implementing personalized medicine.

Authors:  Enrico Mini; Stefania Nobili
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

Review 4.  Genome-wide association studies in pharmacogenomics.

Authors:  Ann K Daly
Journal:  Nat Rev Genet       Date:  2010-04       Impact factor: 53.242

Review 5.  Evidence-based strategies for the optimization of pharmacotherapy in older people.

Authors:  Eva Topinková; Jean Pierre Baeyens; Jean-Pierre Michel; Pierre-Olivier Lang
Journal:  Drugs Aging       Date:  2012-06-01       Impact factor: 3.923

6.  Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research.

Authors:  Rachel Huddart; Alison E Fohner; Michelle Whirl-Carrillo; Genevieve L Wojcik; Christopher R Gignoux; Alice B Popejoy; Carlos D Bustamante; Russ B Altman; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2019-01-21       Impact factor: 6.875

Review 7.  The pharmacogenetics research network: from SNP discovery to clinical drug response.

Authors:  K M Giacomini; C M Brett; R B Altman; N L Benowitz; M E Dolan; D A Flockhart; J A Johnson; D F Hayes; T Klein; R M Krauss; D L Kroetz; H L McLeod; A T Nguyen; M J Ratain; M V Relling; V Reus; D M Roden; C A Schaefer; A R Shuldiner; T Skaar; K Tantisira; R F Tyndale; L Wang; R M Weinshilboum; S T Weiss; I Zineh
Journal:  Clin Pharmacol Ther       Date:  2007-03       Impact factor: 6.875

8.  Natriuretic peptide receptor-3 gene (NPR3): nonsynonymous polymorphism results in significant reduction in protein expression because of accelerated degradation.

Authors:  Naveen L Pereira; Dong Lin; Linda Pelleymounter; Irene Moon; Gail Stilling; Bruce W Eckloff; Eric D Wieben; Margaret M Redfield; John C Burnett; Vivien C Yee; Richard M Weinshilboum
Journal:  Circ Cardiovasc Genet       Date:  2013-03-14

9.  Human betaine-homocysteine methyltransferase (BHMT) and BHMT2: common gene sequence variation and functional characterization.

Authors:  Fang Li; Qiping Feng; Candace Lee; Shuzhan Wang; Linda L Pelleymounter; Irene Moon; Bruce W Eckloff; Eric D Wieben; Daniel J Schaid; Vivien Yee; Richard M Weinshilboum
Journal:  Mol Genet Metab       Date:  2008-05-23       Impact factor: 4.797

10.  Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.

Authors:  Lisa R Treviño; Noriko Shimasaki; Wenjian Yang; John C Panetta; Cheng Cheng; Deqing Pei; Diana Chan; Alex Sparreboom; Kathleen M Giacomini; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.